Atossa Genetics Announces FDA Approval of Oral Endoxifen for "Expanded Access" as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

Stock Information for Atossa Genetics Inc.

Loading

Please wait while we load your information from QuoteMedia.